Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer

NCT04510584 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04510584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04510584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Withdrawn
Start date
July 16, 2021
Completion date
February 22, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian endometrioid tumor, primary peritoneal cancer, tp53 mutation